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Abstract
Tachycardia-induced cardiomyopathy is a systolic cardiac dysfunction given by prolonged 
elevated heart rates in patients with incessant or frequent tachyarrhythmias. Arrhythmias 
associated with tachycardiomyopathy can be either supraventricular (atrial tachycardia, 
atrial flutter, atrial fibrillation, AVNRT, permanent junctional reciprocating tachycardia, 
high rates of atrial pacing) or ventricular (frequent premature ventricular complexes, 
right ventricular outflow tract tachycardia, LVOT, left ventricular fascicular tachycardia, 
bundle-branch reentry or high rate of ventricular pacing). Electrophysiological study con-
firms the clinical diagnosis of tachycardia-induced cardiomyopathy, reveals the arrhythmia 
mechanism and facilitates catheter ablation that results in complete recovery of ventricular 
function. This chapter has two parts: 1. Theoretical insight into the pathogenesis of tachy-
cardia-induced cardiomyopathy, clinical manifestations and therapy. 2. Practical issues: 
we describe our EP lab’s experience on electrophysiological study and ablation in patients 
with tachycardia-induced cardiomyopathy. We will present five cases of ablation: PVCs 
>30,000/24 h, antidromic tachycardia, 2:1 atrial flutter, persistent atrial fibrillation and RVOT 
PVCs with nonsustained VT.
Keywords: catheter ablation, tachycardia-induced cardiomyopathy, atrial fibrillation, 
ejection fraction, left ventricular dysfunction
1. Introduction
Cardiomyopathy is defined by a disease of the heart muscle that progressively worsens and 
ultimately leads to heart failure and death. Fortunately, there are some reversible cardiomyopa-
thies that can show return to normal cardiac function with or without treatment: peripartum 
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cardiomyopathy, myocarditis with dilated cardiomyopathy, hyperthyroidism-induced cardio-
myopathy, takotsubo cardiomyopathy and tachycardia-induced cardiomyopathy. The last one 
is a disease caused by a persistent tachycardia with return to normal cardiac function after cor-
rection of the arrhythmia.
Arrhythmias that are associated with this type of reversible cardiomyopathy include atrial 
fibrillation, atrial flutter, atrial tachycardia, atrioventricular node reentrant tachycardia, acces-
sory pathway tachycardia, frequent ventricular ectopic beats and ventricular tachycardia.
2. Experimental studies on animals
Animal models helped us to better evaluate cellular and hemodynamic mechanisms underly-
ing tachycardia-induced cardiomyopathy. Whipple et al. described it in an interesting experi-
ment on dogs and pigs using cardiac pacing. Chronic rapid ventricular pacing leads to left 
biventricular dilatation and decreases in systolic function. When pacing at slower rate or for 
shorter duration, the degree of dilatation is not so important, as well as the decrease in ejection 
fraction. Mitral regurgitation appears as a consequence of left ventricular dilatation [1].
3. Clinical studies on humans
Multiple tachyarrhythmias have been associated with tachycardia-induced cardiomyopathy 
including supraventricular and ventricular. Additionally, premature ventricular beats have 
also been associated with the development of tachycardia-induced cardiomyopathy.
Gentlesk et al. noted that ablation of arrhythmia with restoration of sinus rhythm can improve 
LV function despite good rate control before the ablation procedure in patients with atrial 
fibrillation [2]. The most recent series of patients with incessant atrial tachycardia reported 
normalization of left ventricular function in 97% of the patients after successful ablation [3]. 
Incessant reentrant supraventricular tachycardias are less common, but tachycardia-induced 
cardiomyopathy has also been reported in the settings of atrioventricular node reentrant 
tachycardia, atrioventricular tachycardia using an accessory pathway and permanent junc-
tional form of reentrant tachycardia [4]. When VT leads to tachycardia-induced cardiomyopa-
thy, it is generally idiopathic, originating from RVOT, LVOT or coronary cusps. Premature 
ventricular contractions have also been associated with the disease.
Medi et al. identified variables associated with tachycardia-induced cardiomyopathy: inces-
sant tachycardia, male gender, mean ventricular rate above 117 bpm and tachycardia originat-
ing from the pulmonary veins or left/right appendage [3].
In recent studies, electrical remodeling was demonstrated to precede structural remodeling 
with subsequent clinical adverse outcomes. In DAVID trial [5], ventricular pacing was associ-
ated with increased rate of heart failure hospitalization and cardiac mortality. The trial was 
designed to test the hypothesis that physiologic heart rates obtained with beta-blockers during 
ventricular pacing improve survival in patients with heart failure. Contrary to logical thinking, 
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ventricular pacing had higher incidence of heart failure and cardiac mortality as mentioned 
above. Recent therapeutic advances using biventricular pacing aim to synchronize electrical 
activation of the left and right ventricle and reverse structural remodeling. This approach may 
be of use for tachycardia-induced cardiomyopathy in patients with ventricular pacing or ven-
tricular premature contractions (left ventricular pacing triggered by right ventricular PVCs) 
but not for tachyarrhythmias [6].
4. Structural changes
Sustained ventricular or atrial pacing leads to dilatation of all cardiac chambers with systolic and 
diastolic dysfunction. Cardiac dilatation is accompanied by ventricular wall thinning and elevated 
ventricular filling pressures with reduced cardiac output. Mitral valve regurgitation appears as 
a consequence of left ventricular dilatation and stretching of the mitral chordae and annulus [7].
5. Neurohormonal changes
Low cardiac output leads to neurohormonal activation with elevated plasma catecholamines, 
atrial natriuretic peptide, rennin and aldosterone [8].
6. Cellular changes
At the cellular level, it has been found that chronic rapid heart rate causes increase in myocite 
length and disruption of the sarcolemmal membrane interface, impairing myocardial function 
[9]. Abnormalities of the sarcoplasmic reticulum calcium transport may appear at 24 h after initi-
ation of rapid atrial pacing and persist 4 weeks after cessation of pacing. The lower availability of 
calcium to myocites may reduce contractility [10]. Besides myocardial energy depletion, myocar-
dial ischemia has been proposed as a possible mechanism for myocardial systolic dysfunction.
7. Tachycardia-induced cardiomyopathy and post-tachycardia T-wave 
memory
Both post-tachycardia T-wave memory and tachycardia-induced cardiomyopathy are two 
phenomenon characterized by electrical remodeling of the ventricles that occur after sustained 
episodes of tachyarrhythmias.
In cardiac memory, the hallmark is diffuse T-wave inversion. It also appears after persis-
tent abnormal ventricular conduction such as ventricular pacing, intermittent bundle-branch 
block or ventricular preexcitation. This phenomenon was described in early 1940s in patients 
with ventricular tachyarrhythmias, but the term of cardiac memory was first introduced 
by Rosenbaum in 1982 [11]. Abnormal ventricular activation causes change in the action 
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potential duration in the early versus late activated regions of the myocardium that results 
in increased transmural repolarization gradient. The duration of inverse T-wave polarity is 
related to the duration of abnormal ventricular conduction and may have short-term or long-
term persistence.
The time course of tachycardia-induced cardiomyopathy can be variable: days to months and 
even years. It is not known why some patients respond to persistent tachycardia with dilation 
of the heart chambers and others by negativation of T-waves.
T-wave inversion lasting minutes to hours are described as short-term memory and are observed 
after short episodes of tachyarrhythmias. Long-term memory lasts hours to days and occurs after 
temporary cessation of a permanent pacing or after a successful ablation of an accessory path-
way. Previous reported cases of transient T-wave inversion following tachycardia failed to show 
an association between duration of the tachycardia and magnitude and duration of the T-wave 
changes. Freundlich reported an episode of ventricular tachycardia lasting 10 min and followed 
by T-wave inversion for 3 weeks [12]. Dubbs and Parmet described a case of VT lasting 21 days 
and followed by T-wave inversion for only 4 days [13]. Campbell reported a case of atrial tachy-
cardia with a duration of 3 days followed by T-wave inversion for other 3 days [14].
8. Time course and recovery of the LV function
The time course of reversal can be variable and may vary from 1 day to several months and 
even years [15]. The factors that determine the improvement rate remain undefined. It is a 
combination of genetic and structural heart disease factors that determine the development of 
the tachycardia-induced cardiomyopathy.
Han et al. [15] reported a patient with dramatic improvement of the LV systolic function <24 h 
after ablation with improvement of symptoms of congestion the first day after ablation.
Chin et al. [16] reported a series of patients who had improvement of the ejection fraction after 
6 months of rate control: two patients with atrial fibrillation treated for heart rate control, two 
patients with atrial tachycardia treated for heart rate control and two patients with severe 
systolic dysfunction EF < 20% and recovery of systolic function after adequate treatment. The 
“slower” the rate control of the tachycardia, the slower the rate of improvement of the systolic 
function of the left ventricle. In contrast, patients with very low ejection fraction <20% have a 
slower rate of improvement. Chin et al. evaluated systolic function using either echocardiog-
raphy or radionuclide angiography [16]. Danadamudi et al. reported patients with ejection 
fraction normalization after 14 months, but elevated left ventricular end-systolic and end-
diastolic volume indexes were still present at follow-up.
9. Risk of recurrence
In patients with prior history of tachycardia-induced cardiomyopathy, recurrence of the 
arrhythmia leads to a more severe form compared to the initial presentation [17].
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10. Clinical features and diagnostic considerations
Arrhythmias associated with tachycardiomyopathy can be supraventricular (atrial tachycar-
dia, atrial flutter, atrial fibrillation, AVNRT, permanent junctional reciprocating tachycardia, 
high rates of atrial pacing) or ventricular (frequent premature ventricular complexes, right 
ventricular outflow tract tachycardia, LVOT, left ventricular fascicular tachycardia, bundle-
branch reentry or high rate of ventricular pacing).
The exact incidence of the disease is difficult to assess, as the most reports in medical literature 
are small retrospective series or case studies.
Tachycardia-induced cardiomyopathy occurs independent of the age: it is present in children 
[18], adolescents [19], adults [20] and aged persons [21]. In children and adolescents, it should 
be differentiated form dilated cardiomyopathy due to myocarditis. In this case, cardiac MRI 
and cardiac biopsy are required to confirm the diagnosis. In adults, other forms of reversible 
cardiomyopathies should be excluded as follows: peripartum cardiomyopathy, myocarditis 
with dilated cardiomyopathy, hyperthyroidism-induced cardiomyopathy and takotsubo car-
diomyopathy. The time course of the cardiomyopathy and lack of arrhythmia can exclude 
tachycardia-induced cardiomyopathy. Paraclinical examinations contribute to the differen-
tial diagnosis. In aged persons, idiopathic dilated cardiomyopathy is the main differential 
diagnosis and the presence of a sustained arrhythmia other than sinus rhythm leads to the 
correct diagnosis.
There is no specific test for the diagnosis of tachycardia-induced cardiomyopathy. A clini-
cal index of suspicion derives from history of symptoms and signs of heart failure and time 
course of arrhythmia. Therefore, a high index of suspicion should be considered in any 
patient with sustained tachyarrhythmia and dilated cardiomyopathy and depressed ejection 
fraction. Any prolonged rate above 120/min may be important for the diagnosis. Patients may 
develop tachycardia-induced cardiomyopathy even if well-controlled heart rates during rest 
and high ventricular rate during minimal activity [22]. Holter monitoring on 24 h may be use-
ful in assessing heart rates during minimal exertion or daily physical activity in patients with 
persistent atrial fibrillation [23].
11. Imaging studies in tachycardia-induced cardiomyopathy
Echocardiography is the cornerstone of the noninvasive imaging of tachycardia-induced car-
diomyopathy. Increase in ejection fraction after arrhythmia treatment with decrease in ven-
tricular diameters is diagnostic for the disease.
Radionuclide ventriculography is another noninvasive diagnostic technique showing left and 
right ventricular dilatation and systolic dysfunction.
Cardiac MRI identifies areas of myocardial fibrosis. Hasdemir et al. demonstrated lack of 
fibrosis in 18 out of 19 patients with tachycardia-induced cardiomyopathy. They concluded 
that PVC-induced cardiomyopathy is less likely to evaluate with fibrosis [24]. This study is 
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consistent with the findings of Redfield et al. who demonstrated in a canine model that inflam-
mation, fibrosis and mitochondrial apoptosis are absent in PVC-induced cardiomyopathy [25].
Myocardial biopsy reveals nonspecific findings with interstitial fibrosis and cellular hypertrophy 
like in other forms of cardiomyopathy [26].
12. Treatment
The cornerstone in this reversible cardiomyopathy is normalization of the heart rate either 
by medication, electrical cardioversion or catheter ablation. This results in decrease in the LV 
dimensions and increase in the LV ejection fraction [27, 28].
Antiarrhythmic drugs that can be used in patients, both pediatric and adults with tachycar-
dia-induced cardiomyopathy, are the commonly used drugs in the Vaughan Williams classifi-
cation: Ia, IB, Ic, II and III (both sotalol and amiodarone) as well as combinations. In the study 
of Moore et al. on pediatric population, most of the patients had amiodarone, beta-blockers 
or sotalol as treatment followed by Ic, Ia and lastly Ib. Ninety-two percent of patients treated 
with amiodarone had a positive response to this drug [29].
The catheter ablation technique depends on the principal mechanism of the arrhythmia: 
abnormal automaticity, triggered activity or reentry. Inappropriate sinus tachycardia is 
caused by enhanced normal automaticity, and ablation is performed in the region of the sinus 
node. Focal atrial tachycardia may be due to automaticity, triggered activity or microreentrant 
mechanism, and ablation is performed at the level of earliest atrial activation site. Typical 
atrial flutter has a macroreentrant circuit, where ablation is achieved at the level of cavo-
tricuspid isthmus. Even though the mechanism of atrial fibrillation is still debated among 
electrophysiologists, drivers located at the level of pulmonary veins and rotors inside the 
left atrium are important in initiation and maintenance of the arrhythmia. Ablation for par-
oxysmal atrial fibrillation consists in pulmonary vein isolation (PVI) and for persistent atrial 
fibrillation PVI plus substrate modification. Atrioventricular nodal reentrant tachycardia is 
caused by a reentrant mechanism. The presence of two pathways within the AV node, slow 
pathway and fast pathway, makes the arrhythmia possible. Under normal condition, ablation 
is performed at the level of the slow pathway. Atrioventricular reentrant tachycardia medi-
ated by an accessory pathway has also a macroreentrant mechanism. The circuit involves an 
accessory pathway that is usually ablated during the procedure.
In the absence of a structural heart disease, most ventricular tachycardias have an automatic 
mechanism or given by triggered activity. For outflow tract tachycardias, ablation is per-
formed at the level of earliest ventricular activation site. Fascicular ventricular tachycardias 
are accepted to have a macroreentrant mechanism involving slow response fibers of the 
Purkinje network. Ablation is usually performed at this level or at the fascicular level (left pos-
tero-inferior or left antero-superior). Ventricular tachycardia in patients with old myocardial 
infarction, nonischemic cardiomyopathy or ventricular dysplasia has a reentry mechanism, 
but usually they are not responsible for tachycardia-induced cardiomyopathy.
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We propose the following algorithm of treatment in patients suspected of tachycardia-
induced cardiomyopathy: antiarrhythmic drugs should be started with the aim of normaliza-
tion of the heart rate; in function of the arrhythmia and associated morbidities, beta-blockers 
can be initiated, than escalated to class IC (propafenone or flecainide) in case of no response 
in heart rate reduction. Amiodarone should be the last antiarrhythmic drug to be tested 
because of its side effects. In case of response to amiodarone with normalization of the heart 
rate and ejection fraction, a diagnosis of tachycardia-induced cardiomyopathy can be made 
and catheter ablation should be proposed. Catheter ablation aims to stop the long-term treat-
ment with amiodarone.
13. Clinical case reports
13.1. Case report 1: PVCs >30,000/24 h
A 19-year-old male patient with >30% PVCs on 24 h was hospitalized for catheter abla-
tion. Echocardiography confirmed tachycardia-induced cardiomyopathy with an EF of 35% 
(Figure 1). Cardiac MRI showed an EF of 37% with no sign of myocarditis or fibrosis. After 
ablation of monomorphic PVCs from the right ventricle (Figure 2), LV systolic function nor-
malized with decrease in the dimensions of the heart chambers. At 3-month follow-up, the 
ejection fraction increased to 55%.
13.2. Case report 2: antidromic tachycardia
A 26-year-old male patient presented episodes of wide QRS tachycardia with depressed ejec-
tion fraction of 40% and a dilated left ventricle (Figure 3). His resting ECG showed short 
PR interval and presence of the delta wave (Figure 4). The abnormal activation of the left 
ventricle with intraventricular dissynchronism led to dilated cardiomyopathy. Beta-blockers 
were ineffective in controlling tachycardia, and catheter ablation was proposed. At 4-week 
follow-up after ablation, left ventricular function recovered with normalization of the end-
systolic and end-diastolic LV diameters.
Figure 1. Bi-dimensional echocardiography apical view and parasternal short axis in a 19-year-old dilated left ventricle 
63/54 with depressed ejection fraction of 35% in a patient with PVC-induced cardiomyopathy.
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13.3. Case report 3: 2:1 atrial flutter
A 52-year-old male patient presented to the cardiology department with dyspnea and leg 
edema. His heart rate was 150 bpm (Figure 5), and blood pressure was 110/50 mmHg. 
Echocardiography revealed depressed ejection fraction of 35% with dilated left ventricle 60/50 
and mitral regurgitation grade 2. Antiarrhythmic drug was ineffective in reducing arrhythmia 
with persistence of high rates 150 bpm after amiodarone, metoprolol and digoxin. He was 
Figure 2. Pacemap inside the right ventricle to identify the origin of PVCs. (A) poor correlation pacemap-clinical PVC; 
(B) good correlation 12/12 pacemap-clinical PVC. At this spot, RF ablation determined complete resolution of PVCs with 
no recurrence. Holter ECG identified 0 ExV/24 h.
Figure 3. Echocardiography apical view before and after ablation of a left lateral accessory pathway with frequent 
episodes of antidromic tachycardia.
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transferred in our department, and after ablation of the tricuspid isthmus sinus, rhythm was 
obtained. At 1-month follow-up, ejection fraction normalized >50% with left ventricular diam-
eters of 45/25 and decrease in mitral regurgitation to grade 1 (Figure 6).
13.4. Case report 4: persistent atrial fibrillation
A 63-year-old male patient presented to our cardiology department an episode of persistent 
atrial fibrillation and heart failure. At physical examination, we noticed a heart rate of 120 bpm 
(Figure 7), arrhythmic, with systolic murmur in the left ventricular area, a blood pressure of 
140/80 mmHg and signs of right heart failure: bilateral edema and hepatomegaly.
Figure 4. Twelve-lead ECG during antidromic tachycardia: wide QRS tachycardia 160/min with positive concordance in 
the precordial leads and negative QRS in lead I and aVL suggesting left lateral accessory pathway.
Figure 5. Twelve-lead ECG during 2:1 atrial flutter in a 52-year-old male patient with tachycardiomyopathy. F waves are 
negative in inferior leads: D2, D3 and aVF and positive in lead V1.
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Ejection fraction was 30% with mild dilatation of the left ventricle 65/55, mitral regurgitation 
grade II, left atrial dilation 53 mm and high pulmonary pressure 60 mmHg (Figure 8). Lab 
tests showed normal CBC, effective anticoagulation with an INR of 3.8, LDL = 53 mg% and 
triglycerides = 65 mg%, normal ASAT = 15 and normal ALAT = 12 mg%. Chest X-ray showed 
increased cardio-thoracic index (Figure 9).
After isolation of the left pulmonary veins (Figure 10), sinus rhythm was obtained. No pulmo-
nary vein potentials were observed at the level of the right pulmonary veins (Figure 11). No 
Figure 6. Echocardiography apical view before and after ablation of the cavo-tricuspid isthmus in a patient with dilated 
cardiomyopathy due to 2:1 typical atrial flutter.
Figure 7. Twelve-lead ECG during atrial fibrillation in a 63-year-old male patient with tachycardiomyopathy. The 
amplitude of the f waves in lead V1 is in favor of a recent onset of atrial fibrillation.
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Figure 8. Echocardiography apical view before isolation of the pulmonary veins showing dilated left ventricle 65/55 mm 
with depressed ejection fraction of 30%, mitral regurgitation grade 2 and a dilated left atrium. Images after ablation at 
3-month follow-up are not available.
Figure 9. Chest X-ray AP view before ablation showing increased cardio-thoracic index.
Role of the Electrophysiologist in the Treatment of Tachycardia-Induced Cardiomyopathy
http://dx.doi.org/10.5772/66515
133
left atrial substrate ablation was necessary for obtaining sinus rhythm. At 3-month follow-up, 
echocardiography in another cardiac department showed a normal ejection fraction of 50% 
with normal left ventricular diameters 52/26, mild dilatation of the left atrium 44 mm and 
mild mitral regurgitation.
13.5. Case report 5: RVOT PVCs and NSVT
A 28-year-old male patient was referred to us because of LV dysfunction, frequent PVCs and 
episodes of nonsustained VT.
Figure 11. Images during the ablation procedure: only the left pulmonary veins were isolated because the right veins 
presented no PVP. On the left side: merge between scanner and NavX-Saint Jude mapped pulmonary veins.
Figure 10. (A) Computed tomography with contrast shows four pulmonary veins: two on the left side and two on the 
right side and (B) X-ray during mapping of the right inferior pulmonary vein in the AP view. No PVPs were detected 
inside this vein.
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Figure 12. Nonsustained VT less than 30 s. The QRS morphology is compatible with RVOT origin: LBBB and inferior 
axis, transition in V4.
Figure 13. Three-dimensional activation mapping using the Navx-Saint Jude system. The earliest potential was recorded 
at the level of antero-septal RVOT (red color). RF ablation at this level stopped PVCs and rendered RVOT VT uninducible 
at stimulation after adrenalin infusion.
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The patient’s main complaint was palpitation with dyspnea during exertion. 
Echocardiography revealed an EF of 40% and mild dilation of the left ventricle. The QRS 
morphology was compatible with RVOT origin (Figure 12), and the high number of PVCs 
>35% on 24 h determined us to perform catheter ablation. After the ablation (Figure 13), no 
more PVC was present at follow-up and LV ejection fraction normalized with decrease in 
LV diameters to normal values.
14. Conclusion
Tachycardia-induced cardiomyopathy should be considered in all patients with depressed 
ejection fraction concomitant with a chronic tachyarrhythmia. It is a reversible cause of heart 
failure, and electrophysiological study and mapping should be considered early in the diag-
nosis and treatment algorithm of those patients. An aggressive approach by catheter ablation 
is important when this type of reversible cardiomyopathy is suspected.
As the clinical impact of ablation is substantial, we recommend it for the reversibility of both 
functional and structural changes induced by the tachyarrhythmia.
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